SRPT News and Press, Sarepta Therapeutics Inc. From 02/25/26

2026-02-25 18:55:37 ET Image source: The Motley Fool. Feb. 25, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-25 16:14:57 ET More on Sarepta Therapeutics Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy - Slideshow Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMB...

Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue Net product revenues for the fourth quarter 2025 totaled $369.6 million, consisting of $259.2 million of PMO...

HCI Group Inc. (HCI) is expected to report $4.87 for Q4 2025 XPEL Inc. (XPEL) is expected to report $0.43 for Q4 2025 Oversea-Chinese Banking Corporation Limited ADR (OVCHY) is expected to report $0.56 for Q4 2025 UMH Properties Inc. (UMH) is expected to report $0.24 for Q4 2025 I...

- Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years - Company is eligible to receive a $40 million milestone payment upon first commercial sale in Japan Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the TD Cowen 46 th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Mass. on Tuesday,...

2026-02-20 11:53:55 ET More on Regenxbio, Sarepta Therapeutics Regenxbio: Cautiously Bullish After FDA Setbacks REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a confere...

2026-02-06 09:10:00 ET The DeepSeek ( DEEPSEEK ) sell-off late last January, followed by the tariff tantrum in early April, caused US stocks to plummet. From peak to trough, the S&P 500 ( SPX ) fell 19% on a closing basis, just shy of bear market territory, while the Tech-he...

– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medic...